UK guideline for the use of HIV post‐exposure prophylaxis 2021. Issue 5 (14th February 2022)

• Record Type: Journal Article
• Authors: Cresswell, Fiona; Asanati, Kaveh; Bhagani, Sanjay; Boffito, Marta; Delpech, Valerie; Ellis, Jayne; Fox, Julie; Furness, Linda; Kingston, Margaret; Mansouri, Massoud; Samarawickrama, Amanda; Smithson, Kat; Sparrowhawk, Alex; Rafferty, Paul; Roper, Tom; Waters, Laura; Rodger, Alison; Gupta, Nadi
• Is Part Of: HIV medicine. Volume 23:Issue 5(2022)
• Page Start: 494
• Page End: 545
• Publication Date: 2022-02-14
• Subjects: HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13208
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: We present the updated British Association for Sexual Health and HIV (BASHH) guidelines for post‐exposure prophylaxis (PEP) to HIV following sexual exposures, occupational exposures and other nonoccupational exposures in the community. This serves as an update to the 2015 BASHH guideline on PEP following sexual exposures and the 2008 Expert Advisory Group on AIDS guidelines on HIV PEP. We aim to provide evidence‐based guidance on best clinical practice in the provision, monitoring and support of PEP for the prevention of HIV acquisition following sexual, occupational and other nonoccupational exposures in the community. The guideline covers when to prescribe PEP, what antiretroviral agents to use and how to manage PEP. This includes (i) evidence of PEP efficacy; (ii) evidence relating to individual‐level efficacy of antiretroviral therapy to prevent the sexual transmission of HIV; (iii) data on the detectable (transmissible) prevalence of HIV in specific populations; (iv) risk of HIV transmission following different types of sexual and occupational exposure; (v) baseline risk assessment; (vi) drug regimens and dosing schedules; (vii) monitoring PEP; (viii) baseline and follow‐up blood‐borne virus testing; (ix) the role of PEP within broader HIV prevention strategies, for example, HIV pre‐exposure prophylaxis (PrEP). The guideline also covers special scenarios such as PEP in pregnancy, breastfeeding and chronic hepatitis B virus infection, and when PEP should be considered in people using HIV PrEP. The guidelines are aimed at clinical professionals directly involved in PEP provision and other stakeholders in the field. A proforma to assist PEP consultations is included. A public consultation process was undertaken prior to finalizing the recommendations.